Single Cell Genomic Profiling of Circulating Tumor Cells for Disease Heterogeneity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and managing metastatic castration-resistant prostate cancer (mCRPC) are limited by heterogeneous responses to therapies and cross-resistance among agents, making it challenging to identify optimal treatment sequences and predict therapeutic outcomes.
Innovation Solution
The method involves performing direct analysis of blood samples using immunofluorescent staining and morphological characterization to identify and enumerate circulating tumor cells (CTCs), followed by isolating and individually characterizing genomic parameters to generate genomic profiles for each CTC, thereby determining disease heterogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If tissue biopsies are used for cancer diagnosis, then the diagnostic method is simple and straightforward, but it fails to detect multiple subpopulations of cancer cells with divergent genetic aberrations
Solution Approach 1:
The patent segments the tumor sample into individual single cells, allowing each cell to be analyzed separately for its unique genomic profile. This segmentation enables detection of multiple cancer cell subpopulations with different genetic aberrations that would be masked in bulk tissue analysis.
Solution Approach 2:
The patent introduces liquid biopsy (circulating tumor cells in blood) as an intermediary diagnostic approach that bridges the gap between simple tissue biopsy and complex multi-omics analysis. This intermediary method captures heterogeneous cancer cell populations without requiring invasive tissue sampling.
2Measurement precision
If liquid biopsy of blood is performed to identify circulating tumor cells, then multiple cancer cell subpopulations can be detected, but the complexity of genomic profiling increases significantly
Solution Approach 1:
The patent performs preliminary enrichment of circulating tumor cells from blood samples before genomic analysis. This preliminary action concentrates the rare cancer cells and removes bulk normal cells, simplifying subsequent genomic profiling while maintaining detection of heterogeneous subpopulations.
Solution Approach 2:
The patent extracts and isolates individual circulating tumor cells from the complex blood matrix, separating the diagnostic target from interfering background elements. This extraction enables focused genomic analysis of cancer cells without the complexity of analyzing entire blood samples.
3Loss of information
If single cell genomic profiling is performed on circulating tumor cells, then disease heterogeneity and therapeutic resistance mechanisms can be characterized, but the cost and time required for analysis increases
Solution Approach 1:
The patent changes the analytical parameters by focusing on specific genomic markers and copy number variations rather than comprehensive whole-genome sequencing of each cell. This parameter optimization reduces analysis time and cost while preserving critical information about disease heterogeneity and resistance mechanisms.
Solution Approach 2:
The patent performs partial genomic profiling of a subset of circulating tumor cells rather than exhaustive analysis of all cells. This partial action captures sufficient information about tumor heterogeneity and resistance mechanisms while significantly reducing time and resource requirements.
4Measurement precision
If comprehensive genomic profiling of all circulating tumor cells is performed, then complete characterization of disease heterogeneity is achieved, but the quantity of resources and complexity required becomes unsustainable
Solution Approach 1:
The patent performs genomic profiling on a representative subset of circulating tumor cells rather than all detected cells. This partial action provides sufficient information about tumor heterogeneity and resistance mechanisms while keeping resource consumption at sustainable levels.
Solution Approach 2:
The patent applies different analytical depths to different cell subsets, performing comprehensive profiling on selected cells of interest while using targeted approaches for others. This local quality differentiation optimizes resource allocation while maintaining accurate heterogeneity characterization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables a more accurate characterization of disease heterogeneity, predicts therapeutic responses, and identifies novel mechanisms of resistance, ultimately aiding in the selection of appropriate treatment strategies for mCRPC patients.
Implementation Method 1
performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells
Data Source
AI summary
The disclosure provides a method of detecting heterogeneity of disease in a cancer patient comprising (a) performing a direct analysis comprising immuno fluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) isolating the CTCs from the sample: (c) individually characterizing genomic parameters to generate a genomic profile for each of the CTCs, and (c) determining heterogeneity of disease in the cancer patient based on the profile. In some embodiments, the cancer is prostate cancer. In some embodiments, the prostate cancer is hormone refractory.